Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Veru Inc (VERU)

Veru Inc (VERU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,498
  • Shares Outstanding, K 14,658
  • Annual Sales, $ 16,890 K
  • Annual Income, $ -37,800 K
  • EBIT $ -34 M
  • EBITDA $ -34 M
  • 60-Month Beta -1.01
  • Price/Sales 2.01
  • Price/Cash Flow N/A
  • Price/Book 2.31

Options Overview Details

View History
  • Implied Volatility 145.89% (-214.20%)
  • Historical Volatility 73.23%
  • IV Percentile 11%
  • IV Rank 12.51%
  • IV High 787.37% on 03/06/25
  • IV Low 54.18% on 07/31/25
  • Expected Move (DTE 4) 0.30 (11.53%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 677
  • Volume Avg (30-Day) 173
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 8,075
  • Open Int (30-Day) 7,689
  • Expected Range 2.28 to 2.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.45
  • Number of Estimates 3
  • High Estimate -0.37
  • Low Estimate -0.60
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.11 +23.22%
on 11/20/25
2.86 -9.09%
on 11/13/25
+0.04 (+1.56%)
since 11/07/25
3-Month
2.11 +23.22%
on 11/20/25
4.59 -43.36%
on 10/08/25
-0.77 (-22.85%)
since 09/08/25
52-Week
2.11 +23.22%
on 11/20/25
14.20 -81.69%
on 01/24/25
-4.54 (-63.58%)
since 12/06/24

Most Recent Stories

More News
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop

MIAMI, FL, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

VERU : 2.60 (+4.42%)
Veru to Present Two Abstracts at ObesityWeek 2025

MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

VERU : 2.60 (+4.42%)
Veru Announces Pricing of $25 Million Public Offering

MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

VERU : 2.60 (+4.42%)
Veru Announces Proposed Public Offering

MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

VERU : 2.60 (+4.42%)
Veru Announces Proposed Public Offering

MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

VERU : 2.60 (+4.42%)
Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

VERU : 2.60 (+4.42%)
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side...

VERU : 2.60 (+4.42%)
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and...

VERU : 2.60 (+4.42%)
Veru Announces Reverse Stock Split

MIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

VERU : 2.60 (+4.42%)
Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th

MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and...

VERU : 2.60 (+4.42%)

Business Summary

Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered...

See More

Key Turning Points

3rd Resistance Point 2.69
2nd Resistance Point 2.62
1st Resistance Point 2.55
Last Price 2.60
1st Support Level 2.41
2nd Support Level 2.34
3rd Support Level 2.27

See More

52-Week High 14.20
Fibonacci 61.8% 9.58
Fibonacci 50% 8.15
Fibonacci 38.2% 6.73
Last Price 2.60
52-Week Low 2.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar